Who is GLP-1 Connect?

GLP-1 Connect was created by Kelly Harris. She personally tested, researched and verified all companies on the list. GLP-1 Connect is a platform that helps connect patients to weight loss providers for GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Zepbound, compounded semaglutide, and compounded tirzepatide.

All vetted companies on the list have been extensively researched before they are put on the list. None of the providers charge a monthly fee or have any hidden fees.

How to Get Started?

CHOOSE WHICH COMPANY IS THE BEST FIT FOR YoU.

STEP 1

Medical Screening

Get started with a quick online screening or schedule a call with our care team to ask questions. Your medical history will be reviewed by a licensed provider to ensure you’re a safe candidate for treatment—no waiting rooms, just thoughtful care from real clinicians.

STEP 2

Delivered to Your Door

‍Once approved, your prescription is sent to a partner pharmacy and shipped straight to your home. No need to visit a clinic—just fast, secure, and discreet delivery so you can begin treatment without the hassle.

STEP 3

Easy At-Home Injections

‍Administer your treatment with confidence from the comfort of home. Injections are simple and self-guided, and if you need support, our nurses are available to support you through your first dose. We’re with you every step of the way.

What is the difference between glp-1 and glp-2?

GLP-1 vs. GLP-2: Understanding their differences

Glucagon-like peptide-1 (GLP-1) and Glucagon-like peptide-2 (GLP-2) are both hormones derived from the same precursor molecule, proglucagon, and secreted by specialized L-cells primarily found in the small intestine and colon following nutrient ingestion. However, despite this shared origin, their primary functions and target organs differ significantly: 

1. Key differences

• Primary Function:

  • GLP-1: Primarily known for its role as an incretin hormone, meaning it potentiates glucose-dependent insulin secretion, according to NIH. It also inhibits glucagon secretion, delays gastric emptying, and suppresses appetite.

  • GLP-2: Primarily characterized by its intestinotrophic effects, promoting the growth, repair, and overall health of the intestinal lining (mucosa). It also influences intestinal absorption, motility, and barrier function.

• Main Target Organs:

  • GLP-1: Primarily acts on the pancreas (beta cells to stimulate insulin, alpha cells to inhibit glucagon), but also impacts the brain (appetite suppression), stomach (gastric emptying), and potentially other areas like the cardiovascular system.

  • GLP-2: Primarily acts on the intestines, particularly the epithelial cells and related structures, to promote cell proliferation and reduce apoptosis, states the American Physiological Society Journal. It also has effects on the central nervous system, according to ScienceDirect.com.

• Clinical Applications:

  • GLP-1: GLP-1 receptor agonists are widely used in the treatment of type 2 diabetes to manage blood sugar levels and promote weight loss. Some GLP-1 based medications have also been approved for obesity management and are being investigated for potential cardiovascular and renal benefits, says Henry Ford Health.

  • GLP-2: GLP-2 analogs (like teduglutide) are used to treat short bowel syndrome, a condition where the body has difficulty absorbing nutrients due to a shortened or damaged small intestine. It helps improve intestinal function and nutrient absorption in such patients. 

2. Shared characteristics

• Gut-Derived Hormones: Both GLP-1 and GLP-2 are produced and secreted by the enteroendocrine L-cells in the gut in response to nutrient intake.

• Rapid Degradation: Both hormones are quickly degraded by the enzyme dipeptidyl peptidase IV (DPP-4), leading to a short half-life in the bloodstream.

• Potential Beyond Primary Roles: While their primary functions differ, research suggests they may have broader impacts. For instance, GLP-1 may have neuroprotective and cardiovascular effects, and GLP-2 may influence glucose metabolism and reduce inflammation